Lead Sponsor

Merck Sharp & Dohme LLC

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•Has End-Stage Renal Disease (ESRD) maintained on stable outpatient hemodialysis (HD) regimen at a healthcare center for \> 3 months prior to dosing.
•On HD regimen at least 3 times per week for a minimum of 3 hours per dialysis session, using a complication-free well-maintained AV fistula or AV graft.
•Is taking clopidogrel for a minimum of 2 weeks prior to the first dosing of MK-2060 administration.
•Has a Body Mass Index (BMI) ≥ 18 and ≤ 45 kg/m\^2.

•History of cancer (malignancy), including adenocarcinoma, except adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up.
•Has a history of deep vein thrombosis or pulmonary embolism.
•Has a history of gastrointestinal (GI) bleeding, duodenal polyps or gastric ulcer in the last 5 years or severe hemorrhoidal bleed in last 3 months prior to screening.
•Is positive for hepatitis B surface antigen or human immunodeficiency virus (HIV).
•Has ongoing anticoagulant therapy or antiplatelet therapy, not including clopidogrel. Intradialytic heparin is permitted.

Related studies

NCT04128189 · Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, and more

NCT04634916 · Kidney Disease, End-Stage, End-stage Renal Disease, and more

NCT06933472 · Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, and more

NCT07224763 · ESRD (End-Stage Renal Disease), Kidney Transplantation, and more

NCT06660277 · Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), and more

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)